Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging
Large‐Scale
Data to Inform Therapeutic Directions
Authors
Keywords
-
Journal
ONCOLOGIST
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-09-21
DOI
10.1634/theoncologist.2020-0509
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy
- (2020) Bo-Duan Xiao et al. World Journal of Stem Cells
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
- (2019) H. S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Allosteric Regulation of Cyclin-B Binding by the Charge State of Catalytic Lysine in CDK1 Is Essential for Cell-Cycle Progression
- (2019) Shaunak Deota et al. JOURNAL OF MOLECULAR BIOLOGY
- Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
- (2019) Andrew L Hong et al. eLife
- Practical treatment strategies and future directions after progression on CDK4/6 inhibition and endocrine therapy in advanced HR+/HER2- breast cancer
- (2019) Sarah Sammons et al. Clinical Breast Cancer
- Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
- (2019) Florian Handle et al. Scientific Reports
- TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity inPTENandTP53-mutated prostate cancer
- (2018) Alexandra M Blee et al. CLINICAL CANCER RESEARCH
- Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)–Deficient Carcinomas of the Urinary System
- (2018) Sumati Gupta et al. Clinical Genitourinary Cancer
- Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives
- (2018) Giuseppe Badalamenti et al. Radiologia Medica
- Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies
- (2018) Dorota Kwapisz Breast Cancer
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities
- (2018) Sherri Z. Millis et al. CANCER
- YAP1-mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in Esophageal Cancer
- (2018) Fan Li et al. CLINICAL CANCER RESEARCH
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
- (2018) Kamal Pandey et al. INTERNATIONAL JOURNAL OF CANCER
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
- (2017) Jiayuan Wang et al. Journal of Translational Medicine
- CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
- (2017) James P. Stice et al. MOLECULAR CANCER RESEARCH
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration
- (2017) Julia A. Elvin et al. ONCOLOGIST
- Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
- (2016) Myrella Vlenterie et al. ANNALS OF SURGICAL ONCOLOGY
- Targeting CDK4/6 in patients with cancer
- (2016) Erika Hamilton et al. CANCER TREATMENT REVIEWS
- Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas
- (2016) Julien Calderaro et al. EUROPEAN UROLOGY
- Gene of the month:SMARCB1
- (2016) Sangeetha N Kalimuthu et al. JOURNAL OF CLINICAL PATHOLOGY
- Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
- (2016) Teresa Helsten et al. MOLECULAR CANCER THERAPEUTICS
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer
- (2016) Ran Zhao et al. EBioMedicine
- Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics
- (2015) Shumei Kato et al. CELL CYCLE
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
- (2015) Maria Schwaederle et al. JOURNAL OF CLINICAL ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Cyclin alterations in diverse cancers: Outcome and co-amplification network
- (2015) Maria Schwaederle et al. Oncotarget
- RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis
- (2013) Riccardo Di Fiore et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
- (2012) Q. Li et al. CLINICAL CANCER RESEARCH
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More